



An Open Label, Single Arm Multi-Centric Study to Assess the Safety and Efficacy of Sodium Feredetate (Fedate Syrup) within 21 Days in Patients with Iron Deficiency Anemia in Ivory Coast

Saurav Deka^{1*}, Isidore Bli B. Die² and Oura N'Guessan³

¹Global Clinical Research, Ajanta Pharmaceutical, Mumbai, India.

²Chef de Service Gynaecology, CHR de Bondoukou, Ivory Coast.

³Hospital General d'Abobo, Abidjan, Ivory Coast.

Authors' contributions

This work was carried out in collaboration between all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/IJR2H/2018/46048

Editor(s):

- (1) Dr. Dharmesh Chandra Sharma, ABTO (Associate Blood Transfusion Officer) Incharge Blood Bank, Component & Aphaeresis Uni, G. R. Medical College & J. A. Hospital, Gwalior India.
(2) Dr. Jianxiang (Jason) Chi, Head of Molecular Haematology Laboratory / Head of CytoGenomics Laboratory The Center for the Study of Haematological Malignancies (CSHM), Karaiskaki Foundation, Cyprus.

Reviewers:

- (1) Paolo Arosio, University of Brescia, Vietnam.
(2) Kojom Foko Loick Pradel, The University of Douala, Cameroon.
(3) Sohaib Bin Nawaz, King Edward Medical University, Pakistan.
Complete Peer review History: <http://www.sdiarticle3.com/review-history/46048>

Original Research Article

Received 21 October 2018

Accepted 04 January 2019

Published 11 January 2019

ABSTRACT

Introduction: Iron deficiency anemia is a common disease prevalent mostly in developing countries Replenishing iron stores via oral route supplementation takes longer time, however for safety reasons it is considered as the most convenient route. There is always search of better oral iron supplement which can replenish the iron deficiency at short duration of time.

Objectives: A post-marketing surveillance study to assess the safety and efficacy of Fedate syrup (Sodium Feredetate) within 21 days in clinical practice.

Materials and Methods: A total 40 patients visiting 2 gynaecologists, who had a hemoglobin (Hb) level of < 10 gm/dl, and had a body mass index (BMI) of < 24 kg /m² were included in the study. All patients were prescribed either 10-15 ml Fedate syrup once or twice a day. Clinical effectiveness

was assessed over a period of 21 days. Treatment response was recorded as responders or non-responders based on a minimum 1 gm/dl increase in Hb levels.

Results: A total of 33 patients (82.5%) responded to the treatment within 21 days as compared to 7 patients (17.5%) who did not respond to the treatment. There was significant difference in global efficacy and assessment of tolerability which was recorded on a scale of poor to excellent. The drug was tolerated well in all patients responding either as “good” or “excellent” to the treatment. Global efficacy was “poor” in 6 patients (15%) and “excellent” in 20 (50%). The paired student’s T-test score for increase in hemoglobin from baseline to 21st day was 5.4995 (P<0.0001).

Conclusions: We conclude that Sodium Feredetate is an effective compound as Fedate syrup in improving the symptoms of anemia in majority of the patients.

Keywords: Iron deficiency anemia; Sodium Feredetate; hemoglobin; and oral iron.

ABBREVIATIONS

ADI : Acceptable Daily Intake
BMI : Body Mass Index
EDTA : Ethylene Diamine Tetraacetic Acid
EDI : Estimated Daily Intake
Hb : Hemoglobin,
IV : Intravenous
IM : Intramuscular
IDA : Iron Deficiency Anemia
JECFA : The Joint FAO/WHO Expert Committee on Food Additives

1. INTRODUCTION

Anemia continues to be a major public health problem worldwide, particularly among females of reproductive age in developing country settings. Anemia impairs health and wellbeing in women and increases the risk of maternal and neonatal adverse outcomes. It affects half a billion women of reproductive age worldwide. In 2011, 29% (496 million) of non-pregnant women and 38% (32.4 million) of pregnant women aged 15–49 years were anemic [1]. The Sub-Saharan Africa is one of the most affected regions - with more than half (53.8%) of children under - 5 years old suffering from anemia and in Africa, 57.1% of pregnant women are anaemic [2]. In Kenya, the prevalence of anemia among pregnant women is 55.1% [2]. When the prevalence of anemia among pregnant women is 40.0% or more, it is considered as a severe public health problem [2]. Prevalence data of iron deficiency anemia among women among of reproductive age (15 – 49) in Ivory Coast was reported at 52.9% in 2016 and among pregnant women was reported at 59.3% thereby resulting in higher prevalence of anemia among children below 5 years of age, which was reported at 73.4% [3].

While there are regional differences, prevalence rates across the states are remarkably similar,

reflecting underlying determinants that include diets low in heme-iron and high in phytates, high levels of malaria and other infectious diseases, and frequent reproductive cycling that decreases iron stores [1].

Severe anemia can have serious consequences and therefore needs urgent treatment. Guidelines in the management of anemia recommend measurement of the serum ferritin level to diagnose iron deficiency anemia. It also recommends, screening of all pregnant women for iron deficiency anemia. Adult men and postmenopausal women with iron deficiency anemia are recommended to be screened for gastrointestinal malignancy. Treatment should involve attending to any diagnosed underlying cause. The aim of the treatment should be to restore Hb concentrations and red cell indices to normal, and replenish iron stores either by oral route or parenteral route. If this cannot be achieved, consideration should be given to further evaluation [4,5,6].

Replenishing iron stores via oral route supplementation takes longer time, however for safety reasons it is considered as the most convenient route. Some people are non-responders to oral iron therapy due to longer durations of supplementation, which is probably why they need to be shifted to parenteral iron therapy. However, it is difficult for the physicians to decide when to make the shift as no clear guidelines are present stating the same. Various iron preparations with different elemental iron content are available in the market [4]. However, most of them are associated with problems like poor oral bioavailability, interaction with food and poor gastrointestinal tolerance. Attempts have been made to overcome the above problems by making complex iron preparations like iron sodium feredetate [4]. Sodium feredetate (sodium iron ethylene diamine tetraacetic acid) is

a ferric iron chelate which is shown to have no food interaction and good bioavailability [7]. It contains iron that is combined with a chemical called EDTA to make sodium ferredetate. This is a unionised form of iron and not an iron salt. Sodium ferredetate breaks down in the gut and releases the iron, which is then absorbed by the body. This unionised form of iron is less likely to cause stomach upsets or discolour teeth than iron supplements that contain iron salts, like ferrous sulphate and was therefore the chosen molecule for this study [8]. Therefore, given the above mentioned supporting data, we chose to conduct our study using sodium ferredetate over the more commonly prescribed ferrous sulphate.

Iron EDTA [sodium iron (Fe³⁺) ethylenediaminetetraacetic acid (EDTA)], shown to have a significant beneficial effect on iron status by increasing iron bioavailability in human diets, Iron EDTA, like other EDTA-metal complexes, dissociates in the gastrointestinal tract to form iron, which is bioavailable, and an EDTA salt; absorption of the metal ion and EDTA are independent. They have a low degree of acute oral toxicity. EDTA compounds are not reproductive or developmental toxicants when fed with a nutrient-sufficient diet or minimal diets supplemented with zinc. In chronic toxicity studies, diets containing as much as 5% EDTA were without adverse effects. An upper-bound estimated daily intake (EDI) of EDTA from iron EDTA (1.15 mg/kg bw/day for the US population) is less than half the acceptable daily intake (ADI) for EDTA of 2.5 mg/kg bw/day established by JECFA [7].

Fedate syrup containing Sodium Ferredetate manufactured by Ajanta Pharmaceutical Limited claims visible improvement an increase of minimum 1 gm/dl hemoglobin (Hb) within 21 days of treatment. The company suggests shifting to parenteral therapy if levels are not raised within 21 days of treatment.

2. MATERIALS AND METHODOLOGY

This prospective interventional study on Fedate syrup was carried out in two institutional clinics; Chef de Service Gynecologie and Hospital general d'Abobo located in Ivory Coast. Data was collected from two practicing gynaecologists, where the patients had visited the doctor either complaining of pelvic pain or as a part of their routine antenatal checkup. A total of 40 female patients were included in the study that were between the ages of 18-40, had a hemoglobin

level of < 10 gm/dl, and had a body mass index (BMI) of < 24 kg /m². Patients over the ages of 40 with baseline Hb > 10 gm/dl, and BMI > 24 kg /m² were excluded in order to specifically treat moderate anemia in the short treatment time. Patients with any chronic illness and history of oral or Intravenous (IV)/ Intramuscular (IM) iron therapy in last two months were also excluded from the study. Patients were informed about the study and were prescribed either 10-15 ml Fedate syrup to be taken once or twice a day post informed consent procedures. Previous studies have indicated adults should take one 5ml spoonful of sodium ferredetate oral solution three times a day, gradually increasing to two 5 ml spoonfuls (10 ml) three times a day [8]. Our study suggested the use of 10-15 ml of Fedate syrup prescribed per the physician's discretion to be taken at least once daily along with meals which would suffice the initial increase of 1 gm/dl in Hb levels.

Clinical features of the patients, diagnosis, duration of illness, concomitant medication, were recorded through case report forms prepared by the gynaecologists at their respective institutional clinics. Baseline Hb at day 0 and day 21 were recorded through a simple blood test capturing the complete blood cell count. Clinical effectiveness was assessed over a period of 21 days and patients were classified as responders or non-responders based on Hb increase of more or less than 1.0 g/dl at day 21 respectively. Investigators also gave an overall assessment of tolerability based on a 4-point scale ranging from excellent to poor. Incidence of adverse events was also recorded to evaluate safety of the given treatment.

2.1 Statistical Analysis

Data were presented as numbers and percentages for clinical features, treatment recommendation, effectiveness of the medicine and adverse events. Paired Student's T- test was performed to examine the increase in hemoglobin from baseline to 21st day of treatment. P value less than 0.05 was considered statistically significant. All analyses were performed in IBM SPSS statistics version 23 (IBM Corp, USA).

3. RESULTS

The most common clinical feature among the patients visiting the gynecologists was pregnancy with anemia (37.5%). Other clinical feature was

Table 1. Common clinical feature with concomitant medication

Common clinical feature	Concomitant medication
Infertility with anemia (7.5%)	Primlout N ,Acfol,Oroperidys
Pelvic pain, irregular menstruation with anemia (12.5%)	Lutenyl,Acfol.Ccal sachets
Pregnancy with anemia (37.5%)	Duphaston,Profenid suppositories
Vaginal infection with anemia (5%)	Antiinflammmtory ,antibiotics ,vitamin C
Gynaecological surgery due to myoma, fibroid, ectopic pregnancy (30%)	Doxy 200, Yodocefol,paracetamol
Anemia due to malaria (7.5%)	Artefan 80/480,Efferalgan,Vitamin C

post-surgical anemia (30%), anemia with infertility (7.5%) and anemia due to malaria (7.5%). For all patients, Fedate syrup was recommended. Fedate alone was prescribed in 15 patients whereas concomitant medications were prescribed in 25 patients along with Fedate. Concomitant medications prescribed are shown in Table 1.

The baseline Hb levels of all patients were grouped into two sections and the baseline Hb levels at day 0 and day 21 were tabulated. The average increase in each group is calculated and represented below in Table 2. There was 1.85 gm /dl and 1.68 gm /dl increase in Hb level in patient group who had baseline Hb below 9 gm /dl and above 9 gm/dl respectively.

Table 2. Baseline Hb level and average increase in Hb levels after 21 days

Baseline Hb level (gm/dl)	Number of patient on day 0	Number of patient on day 21	Average Increase of hemoglobin
< 9	12	1	1.85
9-10	28	6	1.68

All patients were prescribed 10-15 ml of Fedate. 50% Patient taken 10 ml and another 50% patient taken 15 ml fedate syrup orally per day for 21 days. Table 3 represents the patient's dosage.

Table 3. Fedate dosages

Fedate dosage	N (%)
10 ml	20 (50%)
15 ml	20 (50%)

Treatment response was recorded as responders or non-responders. Patients with a minimum of 1 gm/dl increase in baseline hemoglobin level were categorized as responders and patients whose baseline hemoglobin did not raise 1 gm/dl were categorized as non-responders. A total of 33 patients (82.5%) responded to the treatment within 21 days as compared to 7 patients

(17.5%) who did not respond to the treatment. Most of the patients who did not respond to the treatment were pregnant (n=4/7). Our understanding is that the systemic nutritional requirements of these pregnant women were probably a hindrance in increasing their Hb levels. We assume that these patients were complaint with the treatment protocols per conversation with the gynecologists at their follow-ups. Unfortunately, we did not have any further means to ensure the same. However, all patients who did not respond to the treatment were shifted to IV iron as per the objectives of the study and were followed up through their treatment schedules. The paired student's T - test score for increase in hemoglobin from baseline to 21st day was 5.4995 (P<0.0001).

There was significant difference in global efficacy and assessment of tolerability which was measured as "poor" (Severe or serious adverse event(s), which necessitated stoppage of study medication), "Fair" (without medication and did not necessitate stoppage of study medication), "Good" (Mild adverse event(s) reported which subsided with or without medication and did not necessitate stoppage of study medication), and "Excellent" (No adverse events reported). The drug was tolerated well in all patients responding either as "good" or "excellent" to the treatment. Global efficacy was "poor" in 6 patients (15%) and "excellent" in 20 (50%). Fig. 1 represents the global efficacy and assessment of tolerability in all patients.

We also grouped patients in two age groups (18–30 and 30–40) and demonstrated the increase in Hb after 21 days of Fedate syrup in each patient in Fig. 2.

3.1 Safety

Adverse events were reported by 10 patients (25%) predominantly in the responder group. Most common adverse events were abdominal pain and slight vertigo reported in 2 patients (5%). Other adverse events are shown in




Fig. 1. Global efficacy and global assessment of tolerability




Fig. 2. Increase in Hb after 21 days of Fedate syrup in age groups 18-30 and 30-40

Table 4. None of the patients reported any serious adverse events and all the reported events are considered negligible given the overall positive response to the treatment.

Table 4. Adverse events

Adverse event	N (%)
Abdominal pain	2 (5%)
Constipation	1 (2.5%)
Pelvic pain	1 (2.5%)
Lack of energy with excessive sleepiness	1 (2.5%)
Diarrhea	1 (2.5%)
Vertigo	2 (5%)
Fatigue	1 (2.5%)
Nausea	1 (2.5%)

4. DISCUSSION

The present study assessed the safety and efficacy of Fedate syrup within 21 days in patients with iron deficiency anemia. Similar observations have been made by other studies. Sarkate P et al. conducted a randomized study to compare efficacy of sodium ferredetate Vs ferrous fumarate in improving hemoglobin profile in 48 pregnant anemic women. Low doses of sodium ferredetate produced comparable results as higher dose of ferrous fumarate and no adverse effects were reported with sodium ferredetate. Revankar et al conducted another randomized study comparing the efficacy of Sodium Ferredetate with Ferrous Sulphate in treatment of iron deficiency anemia in 74 pregnant women.

Sodium ferredetate (Na Fe EDTA) in iron deficiency anemia led to a significant and rapid rise in hemoglobin levels than that with ferrous sulphate in the study. Singhal et al. compared various iron salts in treating iron deficiency anemia in 250 pregnant women. The study found that Sodium ferredetate had minimum side effects as compared to any other iron salts. In our study 33 out of 40 patients responded to the treatment with minimal side effects [9,10,11,12,13].

Currently there aren't any guidelines discussing clinical determinants and timelines to switch patients from oral to parenteral iron supplementation. Okam et al. [14] suggested that Hb measurements taken 14 days after initiation of oral iron therapy can reliably predict overall response in Hb to oral iron therapy. Accordingly, day 14 Hb may be a useful tool for clinicians in determining when to switch patients from oral to parenteral/IV iron. Our study found that a 1gm/dl increase over a period of 21 days in hemoglobin can be a clinically significant determinant of successful oral therapy. We suggest that patients in whom hemoglobin does not increase by 1 gm/dl within 21 days can be suggested parenteral iron therapy.

5. LIMITATIONS

This was a multi centre, single arm, interventional study design, with a clinical diagnosis followed by limited period of follow up. The single arm focus, small subject population, and short period of follow up are some of the limitations of this study. Given, the short duration of this study, we were unable to record patient compliance through phone calls, or other sophisticated compliance measures. We also were unable to address or monitor any additional nutritional components that would've attributed to iron supplementation. Further studies with multiple arms and long-term follow up are required to find out the efficacy of Fedate syrup in large sets of populations.

6. CONCLUSION

Sodium Ferredetate is an effective compound as Fedate syrup in improving the symptoms of anemia in majority of the patients. There was no difference in the effectiveness when treatment was given alone or along with other concomitant medications. Treatment was tolerated well without clinically significant adverse events.

CONSENT

Patients were treated by physicians in their routine practice. Patient confidentiality was maintained at all points of drafting this manuscript. All treatments were explained thoroughly to the patients and informed consent was obtained for the same.

ETHICAL APPROVAL

Ethical approvals were taken from appropriate ethical institutions.

ACKNOWLEDGEMENT

We thank all patients for participating in this study. Special thanks to Ramkumar Subramanian and Dayan Dang for acquisition of funding and general supervision of this study. Thanks to Siddhesh Sharma and Sanvriti Manjrekar for helping technical editing, language editing, and proofreading.

COMPETING INTERESTS

This trial was sponsored by Ajanta Pharma Limited.

REFERENCES

1. World health organization. Global Nutrition Targets 2025: Anemia policy brief. Available:https://www.who.int/nutrition/publications/globaltargets2025_policybrief_anemia/en/ (Last accessed on: 17-12-2018)
2. Legason ID, Atiku A, Ssenyonga R, Olupot-Olupot P, Barugahare JB. Prevalence of anemia and associated risk factors among children in North-western Uganda: A Cross Sectional Study. BMC Hematol. 2017;17:10. Published 2017 Jul 3. DOI: 10.1186/s12878-017-0081-0
3. Stevens GA, Finucane MM, De-Regil LM, et al. Global, regional, and national trends in hemoglobin concentration and prevalence of total and severe anemia in children and pregnant and non-pregnant women for 1995-2011: A systematic analysis of population-representative data. The Lancet Global Health. 2013;1(1):e16-e25.
4. Goddard AF, James MW, McIntyre AS, et al. Guidelines for the management of iron deficiency anemia. Gut. 2011;60:1309-1316.

5. Matthew w. et al. Iron deficiency anemia: Evaluation and management. Am Fam Physician. 2013;87(2):98-104.
6. Davidsson L, Kastenmayer P, Hurrell RF. Sodium iron EDTA [NaFe(III)EDTA] as a food fortificant: the effect on the absorption and retention of zinc and calcium in women. The American Journal of Clinical Nutrition. 1994;60(2):231–237.
7. Heimbach J, Rieth S, Mohamedshah F, Slesinski R, Samuel-Fernando P, Sheehan T, Borzelleca J. Safety assessment of iron EDTA [sodium iron (Fe₃+ethylenediaminetetraacetic acid]: summary of toxicological, fortification and exposure data. Food and Chemical Toxicology. 2000;38(1):99–111.
8. Available:<https://www.medicines.org.uk>. [Online].; 2017 [cited 2018 December 24]. Available:<https://www.medicines.org.uk/emc/files/pil.8791.pdf>
9. Nicholas J, Kassebaum, Rashmi Jasrasaria, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123:615-624. DOI: 10.1182/blood-2013-06-508325
10. Taner CE, Ekin A, Solmaz U, et al. Prevalence and risk factors of anemia among pregnant women attending a high-volume tertiary care center for delivery. J Turk Ger Gynecol Assoc. 2015;16(4):231-6. Published 2015 Nov 2. DOI: 10.5152/jtgga.2015.15071
11. Sarkate P, Patil A, Parulekar S, Rege NN, Samant BD, Lokhande J, Gupta A, Kulkarni K. A randomised double-blind study comparing sodium ferredetate with ferrous fumarate in anemia in pregnancy. J Indian Med Assoc. 2007;105(5):278:280-1, 284.
12. Revankar et al. Efficacy of Sodium Ferredetate with Ferrous Sulfate in treatment of iron deficiency anemia in pregnant women. International Journal of Reproduction, Contraception, Obstetrics and Gynecology Revankar VM et al. Int J Reprod Contracept Obstet Gynecol. 2017;6(5):1978-1981 Available:www.ijrcog.org pISSN 2320-1770 | eISSN 2320-178
13. Singhal et al. Comparison of various oral iron salts in the treatment of iron deficiency anemia in pregnancy. DOI: 10.5958/2394-2754.2015.00005.3
14. Maureen Okam, Todd Koch, Minh Ha Tran. Clinical criteria for transitioning from oral to IV iron replacement therapy in patients with iron deficiency anemia. Blood. 2014;124:211.

© 2018 Deka et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<http://www.sdiarticle3.com/review-history/46048>